Adaptimmune Therapeutics Investor Relations Material
Latest events
Q1 2025
Adaptimmune Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Adaptimmune Therapeutics plc
Access all reports
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel cell therapies for cancer patients, particularly those with solid tumors. The company utilizes a proprietary cell therapy platform to engineer a patient's own cells to target and fight cancer. Adaptimmune is involved in several phase II clinical trials, including SPEARHEAD-1 for synovial sarcoma and SURPASS-3 for platinum-resistant ovarian cancer. Their research and development efforts are supported by strategic collaborations with entities like Genentech, Inc. and F. Hoffman-La Roche Ltd, among others, to further the development and potential commercialization of their therapies. The company is headquartered in Abingdon, United Kingdom, and its shares are listed on the NASDAQ.
Key slides for Adaptimmune Therapeutics plc
FDA Announcement
Adaptimmune Therapeutics plc
FDA Announcement
Adaptimmune Therapeutics plc
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
ADAP
Country
🇺🇸 United States